Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo

RegulatoryapprovedAC-201Positive

AI Analysis

Summary

Accro Bioscience announced IND clearance from China's NMPA for AC-201, a selective TYK2/JAK1 inhibitor, to initiate a Phase II/III clinical trial in non-segmental vitiligo. The development is being conducted in partnership with Shanghai Fosun Pharmaceutical.

Clinical Trial Data

Phase

Phase II/III

Outcome Details

IND clearance from NMPA for Phase II/III clinical trial

Importance:6/10

Sentiment:

0.80

IND clearanceNMPA approvalTYK2/JAK1 inhibitorvitiligoChinaclinical trial

Related Companies

$BHIC $INTI $CHHE

Read the original article

Published by PR Newswire Pharma on September 8, 2026 12:20 PM

Read Original